For US Healthcare Professionals
XARELTO®: Chronic coronary artery disease (CAD) and peripheral artery disease (PAD) treatment
In CAD and/or PAD, dual pathway inhibition with the XARELTO® vascular dose* targets both clotting mechanisms at once1
†XARELTO® 2.5 mg twice daily with aspirin (75 mg to 100 mg) once daily.
The clinical significance of this mechanistic information has not been established.
*Patients with chronic coronary syndromes (chronic CAD) and in sinus rhythm.
CAD = coronary artery disease; DOAC = direct oral anticoagulant; ESC = European Society of Cardiology; PAD = peripheral artery disease.